M. Cazzola (Naples, Italy), S. Rennard (Omaha, United States Of America)
The influence of smoking on COPD phenotypes
J. C. Ratoff, M. W. Lethbridge, T. Snape, H. W. Wong, C. J. Corrigan, B. J. O‘Connor (London, United Kingdom)
|  |
Expression of M3 receptors in bronchi from COPD compared to normals and smokers subjects
G. Caramori, P. Casolari, I. M. Adcock, E. Jazrawi, K. F. Chung, A. Ciaccia, A. Papi, P. J. Barnes (Ferrara, Italy; London, United Kingdom)
| |
Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients
M. Profita, R. Di Giorgi, A. Sala, A. Bonanno, L. Riccobono, F. Mirabella, M. Gjomarkaj, G. Bonsignore, J. Bousquet, A. M. Vignola (Palermo, Milano, Italy; Montpellier, France)
| |
Comparison of the short-term effect of tiotropium (TIO) vs a combination therapy with single inhaler budesonide/formoterol (symbicort) on the degree of pulmonary hyperinflation
P. Santus, M. Verga, F. Di Marco, B. Boveri, M. G. Matera, S. Centanni, M. Cazzola (Milan, Naples, Italy)
| |
Phosphodiesterase expression and activity in human airways
R. A. Clayton, A. Mackenzie, C. A. J. Dick, S. F. Hastings, A. Cooreman, V. Anikin, S. J. MacKenzie (Glasgow, Bradford, United Kingdom)
| |
Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD
K. F. Rabe, D. O‘Donnell, J. F. Muir, C. Jenkins, S. Witte, D. Bredenbroeker, T. D. Bethke (Leiden, The Netherlands; Kingston, Canada; Rouen, France; Camperdown, Australia; Konstanz, Germany)
| |
Budesonide reduces superoxide and peroxynitrite chemiluminescence during human neutrophil bursts
P. C. Braga, M. Culici, M. Dal Sasso (Milan, Italy)
| |